Nobivac Rabies

País: Regne Unit

Idioma: anglès

Font: VMD (Veterinary Medicines Directorate)

ingredients actius:

Rabies virus

Disponible des:

MSD Animal Health UK Limited

Codi ATC:

QI07AA02

Designació comuna internacional (DCI):

Rabies virus

formulario farmacéutico:

Suspension for injection

tipo de receta:

POM-V - Prescription Only Medicine – Veterinarian

Grupo terapéutico:

Cats, Dogs

Área terapéutica:

Inactivated Viral Vaccine

Estat d'Autorització:

Authorized

Data d'autorització:

2005-10-25

Fitxa tècnica

Revised December 2021
AN: 00974/2021
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac Rabies Suspension for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml dose contains:
ACTIVE SUBSTANCE:
Inactivated rabies virus strain Pasteur RIV:
≥ 0.95 AIU* equivalent to ≥ 2 IU**
_ * Batch control is performed with an in vitro potency test according
to Ph. Eur. monograph 451._
_ AIU = rabies antigenic mass AlphaLISA International Units._
_** Corresponding potency in the in vivo mouse challenge test
according to Ph. Eur. Monograph 451._
ADJUVANT:
Aluminium phosphate (adjuvant)
0.60 - 0.88 mg Al
3+
EXCIPIENTS:
Thiomersal (preservative)
0.1 mg
For the full list of excipients see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection.
Light yellow/orange to slightly red/purple with a whitish sediment.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs and cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunisation against rabies to reduce clinical signs
and mortality.
Onset of immunity:
an adequate serological response (

0.5 IU) has been
demonstrated 2 to 3 weeks after vaccination.
Duration of immunity: 3 years.
4.3
CONTRAINDICATIONS
None.
Revised December 2021
AN: 00974/2021
Page 2 of 5
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Vaccinate healthy animals only.
The
vaccine may
not
be effective
in
animals
incubating
the
disease
at
the
time
of
vaccination.
Some animals may be immunologically incompetent and fail to respond to
vaccination. A
good immune response is reliant on the reaction of an immunogenic
agent and a fully
competent immune system. Immunocompetence of the animal may be
compromised by a
variety of factors including poor health, nutritional status, genetic
factors, concurrent drug
therapy and stress.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
The presence of maternal antibodies can interfere with the response to
vaccination.
This product should not be administered for at least one mo